reports
- Research Team ACF
KDST + NLSP Combined Core Investment Case 29052025
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Johnson & Johnson and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 April 2025 in which we reassessed the appropriateness of the ratings in the context of ...
Moody's Ratings says J&J's talc overhang remains after court ruling, b...
Moody's Ratings (Moody's) said that Johnson & Johnson's ("J&J") talc overhang remains after its latest talc subsidiary bankruptcy attempt was denied in courts, but its strong business profile and financial flexibility mitigate ongoing litigation pressures. There is no change at this time to J&J's ra...
- Research Team ACF
ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...
Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...
LLY ELI LILLY AND COMPANY
CFSL COCA-COLA FEMSA SAB DE CV (ADR)
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
AKOB EMBOTELLADORA ANDINA S.A. SERIES B ADS
FMX FOMENTO ECONOMICO MEXICANO S.A.B. DE C.V. ADS
BMTA BRITISH AMERICAN TOBACCO PLC ADS
PM PHILIP MORRIS INTERNATIONAL INC.
ABBV ABBVIE INC.
CCHGY COCA-COLA HBC AG
ABT ABBOTT LABORATORIES
AZN ASTRAZENECA PLC ADS
GSK. GLAXOSMITHKLINE PLC CEDEAR
IMBBY IMPERIAL BRANDS PLC
Moody's Ratings assigns Aaa ratings to Johnson & Johnson's sr. notes; ...
Moody's Ratings (Moody's) assigned Aaa ratings to the new senior unsecured note offerings of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains unchanged at stable. Proc...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...
NTRA NATERA
MMSI MERIT MEDICAL SYSTEMS INC.
MDT MEDTRONIC PLC
LINC LINCOLN EDUCATIONAL SERVICES
FMS FRESENIUS MEDICAL CARE AG & CO. KGAA ADS
BMY BRISTOL-MYERS SQUIBB COMPANY
APEI AMERICAN PUBLIC EDUCATION
BSX. BELO SUN MINING CORP.
PEN PANORO ENERGY ASA
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
DGS. DIVIDEND GROWTH SPLIT
GH GUARDANT HEALTH
STRA STRATEGIC EDUCATION INC.
LRN STRIDE INC
LH LABCORP HOLDINGS INC
GSK GSK PLC
PROD PROSVETNO DELO AD ORD
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...
SYK STRYKER CORPORATION
GBX GREENBRIER COMPANIES INC.
TRN TRINITY INDUSTRIES INC.
MMSI MERIT MEDICAL SYSTEMS INC.
MDT MEDTRONIC PLC
ISRG INTUITIVE SURGICAL INC.
INGN INOGEN INC.
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
GMED GLOBUS MEDICAL INC CLASS A
CRY CRYOLIFE INC.
PEN PENUMBRA INC.
BSX. BELO SUN MINING CORP.
SIBN GAZPROM NEFT PJSC
GATX GATX CORPORATION
RAIL FREIGHTCAR AMERICA INC.
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
OFIX ORTHOFIX MEDICAL INC.
ECOR ELECTROCORE INC.
Moody's Ratings affirms J&J's Aaa ratings; stable outlook
Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa medium term note rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows the announcement that J&J w...
- MarketLine Department
Saponia dd - Company Profile and SWOT Analysis
Summary Saponia dd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Saponia dd (Saponia) is a manufacturer and distributor of home care and personal hygiene products. The company offers a wide range of products including laundry detergents, dish detergents, cleaning products...
Johnson & Johnson: 1 director
A director at Johnson & Johnson maiden bought 1,000 shares at 147.220USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Titan Announces the Closing of Conavi’s Private Placement of Subscript...
Titan Announces the Closing of Conavi’s Private Placement of Subscription Receipts and Provides Update on the Transaction TORONTO, Ontario, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that, in connection with its amalgamation agreement (“Amalgamation Agreement”) with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction (the “Transaction”), Conavi has closed its previously announced concurrent private placement of subscription receipts (“Subscription Receipts”) for gross pr...
Titan Announces Resignations of Directors
Titan Announces Resignations of Directors TORONTO, Ontario, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that following its annual general meeting held on September 30, 2024 (the “Meeting”) and in accordance with Titan’s Majority Voting Policy (the “Voting Policy”), Anthony Giovinazzo, Cathy Steiner, Cary Vance and Paul Cataford have tendered to the Board of Directors (the “Board”) their resignations as directors of Titan (including Paul Cataford’s resignation as Board Chairman). Pursuant to the Voting Policy, the Corporate Governance a...
Titan Reports Voting Results from 2023 Annual General and Special Meet...
Titan Reports Voting Results from 2023 Annual General and Special Meeting TORONTO, Ontario, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announced the voting results from its Annual General and Special Meeting of Shareholders (the “AGM”) held virtually via live audio webcast on September 30, 2024. Shareholders voted in favour of all management resolutions proposed in Titan’s management information circular dated August 30, 2024 (the “Circular”). Resolutions proposed and approved at the AGM include: fixing the number of directors and election of ...
Titan Medical begins process to move to the TSX Venture Exchange
Titan Medical begins process to move to the TSX Venture Exchange TORONTO, Ontario, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that its board of directors (the “Board”) has approved the voluntary delisting (the “Delisting”) of Titan’s common shares (the “Titan Shares”) from the Toronto Stock Exchange (the “TSX”). Subject to approval by the TSX and the completion of all closing conditions for the Transaction (defined below) it is expected that the Titan Shares will be delisted from the TSX effective as of close of markets between October...
Conavi Medical Shareholders Approve the Proposed Amalgamation Between ...
Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi Titan’s respective annual general and special meeting of shareholders to vote on the amalgamation transaction to take place on September 30, 2024, at 4:00 p.m. Eastern Time TORONTO, Ontario, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that Conavi Medical Inc. (“Conavi”) has received the requisite shareholder approval required to proceed with the proposed combination of Titan and Conavi (the “Amalgamation”) in an all-stock transaction (...
Proxy Deadline Thursday September 26, 2024
Proxy Deadline Thursday September 26, 2024 TORONTO, Ontario, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) released a reminder for shareholders to vote ahead of Titan’s annual and special shareholders meeting (the “Meeting”) scheduled to be held on Monday, September 30, 2024. Less than half of the Titan common shares have been voted in advance of the Meeting. VOTE TODAY. The Management Information Circular (the “Circular”) and related materials for the Meeting are available on Titan’s website at and under Titan’s SEDAR+ profile at . Fo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.